fda compounding semaglutide crackdown news november 2025 Beyond the Headlines: Warning Letters to GLP-1 Compounders Important Update: Changes to Compounded

Then the question is, All right, these people stopped publishing

Introduce one variable at a time so you can identify what your body specifically tolerates and what it does not

Around half of the patients that I see in my cardiovascular practice have levels of weight equivalent to those in the select trial and are likely to derive benefit from taking semaglutide. The effect on cardiovascular health was independent of any weight loss

She is currently in the midst of a study that explores how GLP-1s might influence addictive behaviors at the biological level

10.1056/NEJMoa1109400

Eli Lilly received FDA approval for its tirzepatide-based GLP-1 products, Mounjaro for diabetes and Zepbound for weight loss in May 2022 and November 2023, respectively